Pearl on track for 2012 pivotal COPD studies thanks to Phase IIb progress
This article was originally published in Scrip
Executive Summary
Pearl Therapeutics has reported positive results from a Phase IIb, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI), PT005, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), data which the company said would help it to progress another compound, PT003, into Phase III trials.